Abstract
Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase that belongs to the Insulin receptor subfamily involved as full length receptor in neural development. Even if the expression of ALK protein is down-regulated in the adults, the ALK full length is expressed in different types of tumors. Moreover, chromosomal rearrangements, involving the alk gene, can occur leading to the formation of different ALK fusion proteins characterized by the kinase domain of ALK fused to several partners that determine cellular localization. Structural investigation and characterization of the ALK kinase domain in absence of its crystal structure constituted the basis of development of ALK small molecule inhibitors. Here, we described normal function of the ALK receptor and its role in tumors; formation of the constitutively activated ALK fusion proteins and we reported an update of developed small molecule inhibitors of the ALK kinase activity.
Keywords: Anaplastic Lymphoma kinase (ALK), Modeling, Molecular targeting, Oncogenic fusion protein, Small molecule inhibitors, Targeted cancer therapy, tyrosine kinase, alk gene, constitutively activated ALK fusion proteins, non-Hodgkin's lymphoma, Immunohystochemical studies, pleiotrophin(PTN) and midkine (MK), histological defects, glioblastoma, breast cancer
Current Topics in Medicinal Chemistry
Title: The ALK Gene, An Attractive Target for Inhibitor Development
Volume: 11 Issue: 11
Author(s): Carmen J. Tartari, Leonardo Scapozza and Carlo Gambacorti-Passerini
Affiliation:
Keywords: Anaplastic Lymphoma kinase (ALK), Modeling, Molecular targeting, Oncogenic fusion protein, Small molecule inhibitors, Targeted cancer therapy, tyrosine kinase, alk gene, constitutively activated ALK fusion proteins, non-Hodgkin's lymphoma, Immunohystochemical studies, pleiotrophin(PTN) and midkine (MK), histological defects, glioblastoma, breast cancer
Abstract: Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase that belongs to the Insulin receptor subfamily involved as full length receptor in neural development. Even if the expression of ALK protein is down-regulated in the adults, the ALK full length is expressed in different types of tumors. Moreover, chromosomal rearrangements, involving the alk gene, can occur leading to the formation of different ALK fusion proteins characterized by the kinase domain of ALK fused to several partners that determine cellular localization. Structural investigation and characterization of the ALK kinase domain in absence of its crystal structure constituted the basis of development of ALK small molecule inhibitors. Here, we described normal function of the ALK receptor and its role in tumors; formation of the constitutively activated ALK fusion proteins and we reported an update of developed small molecule inhibitors of the ALK kinase activity.
Export Options
About this article
Cite this article as:
J. Tartari Carmen, Scapozza Leonardo and Gambacorti-Passerini Carlo, The ALK Gene, An Attractive Target for Inhibitor Development, Current Topics in Medicinal Chemistry 2011; 11 (11) . https://dx.doi.org/10.2174/156802611795589593
DOI https://dx.doi.org/10.2174/156802611795589593 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Repositioning the Old Fungicide Ciclopirox for New Medical Uses
Current Pharmaceutical Design Application of Serial Analysis of Gene Expression in Cancer Research
Current Pharmaceutical Biotechnology Targets for Anti-metastatic Drug Development
Current Pharmaceutical Design Editorial (Thematic Issue: Targeted Anti-Cancer Drug Delivery)
Current Cancer Drug Targets Stem Cell Transplantation in Pediatric Leukemia and Myelodysplasia: State of the Art and Current Challenges
Current Stem Cell Research & Therapy Application and Interpretation of Genome-Wide Association (GWA) Studies for Informing Pharmacogenomic Research - Examples from the Field of Age-Related Macular Degeneration
Current Molecular Medicine Purine Nucleoside Analogues for the Treatment of Hematological Malignancies: Pharmacology and Clinical Applications
Current Cancer Drug Targets Editorial (Hot Topic:Aspergillosis: New Insights into Disease, Diagnostic and Treatment)
Current Pharmaceutical Design De Novo Design of New Inhibitor of Mutated Tyrosine-Kinase for the Myeloid Leukemia Treatment
Current Pharmaceutical Design Contribution of Latin American Countries to Cancer Research and Patent Generation: Recent Patents
Recent Patents on Anti-Cancer Drug Discovery The physics for the formation of cell-in-cell structures.
Current Molecular Medicine Targeting Heat Shock Protein 90 for Malaria
Mini-Reviews in Medicinal Chemistry Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Dendritic Cells and the Promise of Therapeutic Vaccines for Human Immunodeficiency Virus (HIV)-1
Current HIV Research Regulating miRNA by Natural Agents as a New Strategy for Cancer Treatment
Current Drug Targets Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases
Current Drug Safety Clinical Presentation, Outcome and Risk Factors of Late-Onset Non- Infectious Pulmonary Complications After Allogeneic Stem Cell Transplantation
Current Stem Cell Research & Therapy Targeting Cancer Cells by an Oxidant-Based Therapy
Current Molecular Pharmacology MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential
Current Genomics Combined Effect of Parthenolide and Various Anti-cancer Drugs or Anticancer Candidate Substances on Malignant Cells in vitro and in vivo
Mini-Reviews in Medicinal Chemistry